NCT00819091 - Randomized, Double-blind (db), Placebo-controlled 18 Week Study of Linagliptin (BI 1356) in Type 2 Diabetic Patients With Insufficient Glycaemic Control on a Sulfonylurea Drug | Biotech Hunter

Enrollment

245

Participants

Timeline

Start Date

December 31, 2008

Primary Completion Date

January 31, 2010

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

BI 1356

5mg orally (po) tablet qd

DRUG

Placebo

Placebo matching BI 1356 5mg one tablet daily

Trial Locations (45)

Unknown

1218.35.10002 Boehringer Ingelheim Investigational Site, Birmingham

1218.35.10001 Boehringer Ingelheim Investigational Site, Los Angeles

1218.35.10016 Boehringer Ingelheim Investigational Site, National City

1218.35.10017 Boehringer Ingelheim Investigational Site, Fort Lauderdale

1218.35.10021 Boehringer Ingelheim Investigational Site, Fort Lauderdale

1218.35.10013 Boehringer Ingelheim Investigational Site, Chicago

1218.35.10015 Boehringer Ingelheim Investigational Site, Flint

1218.35.10018 Boehringer Ingelheim Investigational Site, Asheville

1218.35.10004 Boehringer Ingelheim Investigational Site, Cincinnati

1218.35.10005 Boehringer Ingelheim Investigational Site, Portland

1218.35.10020 Boehringer Ingelheim Investigational Site, Greenville

1218.35.10009 Boehringer Ingelheim Investigational Site, Dallas

1218.35.10019 Boehringer Ingelheim Investigational Site, Sugar Land

1218.35.54003 Boehringer Ingelheim Investigational Site, Capital Federal

1218.35.54005 Boehringer Ingelheim Investigational Site, Corrientes

1218.35.54001 Boehringer Ingelheim Investigational Site, Mar del Plata

1218.35.54006 Boehringer Ingelheim Investigational Site, Parque Velez Sarfield

1218.35.36001 Boehringer Ingelheim Investigational Site, Budapest

1218.35.36002 Boehringer Ingelheim Investigational Site, Budapest

1218.35.36004 Boehringer Ingelheim Investigational Site, Budapest

1218.35.36005 Boehringer Ingelheim Investigational Site, Budapest

1218.35.36003 Boehringer Ingelheim Investigational Site, Debrecen

1218.35.91003 Boehringer Ingelheim Investigational Site, Aligarh, Uttar Pradesh

1218.35.91007 Boehringer Ingelheim Investigational Site, Aminjikarai, Tamilnadu

1218.35.91001 Boehringer Ingelheim Investigational Site, Bangalore, Karnataka

1218.35.91004 Boehringer Ingelheim Investigational Site, Bangalore, Karnataka

1218.35.91002 Boehringer Ingelheim Investigational Site, Indore

1218.35.91008 Boehringer Ingelheim Investigational Site, Mumbai, Maharastra

1218.35.91005 Boehringer Ingelheim Investigational Site, Nagpur, Maharashtra

1218.35.91006 Boehringer Ingelheim Investigational Site, Pune, Maharastra

1218.35.81003 Boehringer Ingelheim Investigational Site, Osaka, Osaka

1218.35.81001 Boehringer Ingelheim Investigational Site, Shinjyuku-ku,Tokyo

1218.35.81002 Boehringer Ingelheim Investigational Site, Suita, Osaka,

1218.35.48002 Boehringer Ingelheim Investigational Site, Bialystok

1218.35.48004 Boehringer Ingelheim Investigational Site, Lublin

1218.35.48003 Boehringer Ingelheim Investigational Site, Poznan

1218.35.48001 Boehringer Ingelheim Investigational Site, Rzeszów

1218.35.48005 Boehringer Ingelheim Investigational Site, Wroclaw

1218.35.70008 Boehringer Ingelheim Investigational Site, Arkhangelsk

1218.35.70001 Boehringer Ingelheim Investigational Site, Saint Petersburg

1218.35.70002 Boehringer Ingelheim Investigational Site, Saint Petersburg

1218.35.70003 Boehringer Ingelheim Investigational Site, Saint Petersburg

1218.35.70006 Boehringer Ingelheim Investigational Site, Saint Petersburg

1218.35.70009 Boehringer Ingelheim Investigational Site, Saint Petersburg

1218.35.70007 Boehringer Ingelheim Investigational Site, Yaroslavl